Imperva (IMPV) Earns Daily Coverage Optimism Rating of 0.18

News articles about Imperva (NYSE:IMPV) have been trending somewhat positive recently, AlphaOne Sentiment Analysis reports. The research firm, a service of Accern, rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Imperva earned a daily sentiment score of 0.18 on AlphaOne’s scale. AlphaOne also gave media stories about the software maker an impact score of 93 out of 100, meaning that recent news coverage is extremely likely to have an effect on the stock’s share price in the next several days.

These are some of the news articles that may have effected AlphaOne’s scoring:

Insider Buying and Selling by Quarter for Imperva (NYSE:IMPV)

Shares of Imperva (NYSE IMPV) traded up 0.31% on Friday, reaching $48.25. 723,801 shares of the company’s stock traded hands. The company has a 50 day moving average price of $48.38 and a 200 day moving average price of $42.81. Imperva has a 52 week low of $34.40 and a 52 week high of $57.24. The firm’s market capitalization is $1.61 billion.

Imperva (NYSE:IMPV) last announced its quarterly earnings data on Thursday, May 4th. The software maker reported ($0.29) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.62) by $0.33. Imperva had a negative net margin of 25.60% and a negative return on equity of 28.37%. The firm had revenue of $72.31 million for the quarter, compared to the consensus estimate of $68.16 million. During the same period in the previous year, the firm posted ($0.25) earnings per share. The firm’s revenue was up 21.0% on a year-over-year basis. On average, equities research analysts predict that Imperva will post $0.45 earnings per share for the current fiscal year.

Several analysts have recently commented on IMPV shares. Monness Crespi & Hardt started coverage on shares of Imperva in a research report on Tuesday, March 14th. They set a “buy” rating and a $52.00 price target on the stock. Evercore ISI reaffirmed a “buy” rating and set a $56.00 price target on shares of Imperva in a research report on Monday, May 15th. Susquehanna Bancshares Inc began coverage on Imperva in a research report on Wednesday, June 7th. They issued a “positive” rating and a $60.00 target price on the stock. TheStreet raised Imperva from a “d” rating to a “c” rating in a research report on Thursday, May 4th. Finally, DA Davidson reissued a “buy” rating and issued a $55.00 target price on shares of Imperva in a research report on Wednesday, March 22nd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the company’s stock. Imperva has a consensus rating of “Buy” and an average price target of $49.03.

ILLEGAL ACTIVITY WARNING: This story was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at

In other news, SVP Sunil D. Nagdev sold 4,857 shares of the business’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $49.00, for a total value of $237,993.00. Following the completion of the sale, the senior vice president now directly owns 16,290 shares in the company, valued at $798,210. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CRO Michael D. Mooney sold 52,356 shares of the business’s stock in a transaction on Wednesday, May 10th. The stock was sold at an average price of $47.51, for a total transaction of $2,487,433.56. Following the completion of the sale, the executive now owns 52,356 shares of the company’s stock, valued at $2,487,433.56. The disclosure for this sale can be found here. Insiders have sold 63,387 shares of company stock worth $3,005,338 over the last ninety days. 2.20% of the stock is currently owned by insiders.

Imperva Company Profile

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.

Receive News & Ratings for Imperva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply